KDM4B has been reported to interact with MYC to demethylate H3 K9 me3, thereby activating cyclin B1 (CCNB1) transcription and promoting cell proliferation, suggesting potential for targeting KDM4B in MYC-amplified GBM [217]. Here, KDM4B is linked to glioblastoma.